The United Kingdom and the United States have announced a major bilateral deal that will preserve no import taxes on British medicine shipments being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost funding on medicines through the public health system. This move secures that import taxes on these crucial exports will be held at zero for a period of three years.
This development comes after previous warnings to significantly raise import taxes on patented drug products, with figures discussed as high as one hundred percent.
"This deal with the United Kingdom reinforces the worldwide climate for new treatments and brings long-overdue balance to transatlantic pharmaceutical trade," a release said.
Commercial Importance
Drugs represent one of the the United Kingdom's most significant export categories to the America, which is easily the biggest destination for leading UK drugmakers.
Trade data indicate that in the year prior to last September, the UK shipped medicines valued at over eleven billion pounds to the US. This amount accounted for 17.4% of British export trade in that timeframe.
"This deal protects employment, stimulates capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The deal entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to raise overall NHS spending on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. Previously, repayments topped twenty percent.
Broader Context
The pact takes place against a long-running tension between the drug companies and the ministers over spending levels and NHS adoption.
This friction were intensified by assertions that US patients were charged a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been delayed or scrapped, while major expansions have been pledged toward projects in the United States.
One official stated that the NHS must invest a greater share on treatments, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
